CD117 plays a significant role in the development and progression of certain cancers. It can promote cell proliferation, survival, and migration, contributing to tumor growth and metastasis. In GISTs, activating mutations in the KIT gene lead to constitutive activation of the CD117 receptor, driving tumor development. Targeted therapies, such as imatinib, have been developed to inhibit the activity of CD117 in these tumors, improving patient outcomes.
